| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g |
Purity: ≥98%
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Following rapid intravenous injection, the mean peak serum total tetrahydrofolate (THF) concentration reached 1722 ng/mL. The mean peak serum (6S)-5-methyl-5,6,7,8-tetrahydrofolate concentration reached 275 ng/mL, with a mean time to peak of 0.9 hours. Urine. Data missing. Data missing. Duration of action: All routes of administration: 3 to 6 hours. Time of onset: Oral: 20 to 30 minutes. Intramuscular: 10 to 20 minutes. Intravenous: Less than 5 minutes. Moderate amounts cross the blood-brain barrier; primarily concentrated in the liver. Excretion: Kidney: 80-90%. Feces: 5-8%. For more complete data on the absorption, distribution, and excretion of leucovorin calcium (10 types), please visit the HSDB record page. Metabolism/Metabolites Extensively converted to tetrahydrofolate derivatives.In vivo, calcium folinate is rapidly and extensively converted to other tetrahydrofolate derivatives, including 5-methyltetrahydrofolate, which is the main transport and storage form of folate in the body. /Calcium folinate/ Primarily metabolized in the liver and intestinal mucosa to 5-methyltetrahydrofolate (active form). After oral administration, calcium folinate is metabolized in large quantities (greater than 90%) and rapidly (within 30 minutes). The degree of metabolism is lower after intravenous injection (approximately 66%), and approximately 72% after intramuscular injection; the rate of metabolism is slower after parenteral administration. Biological Half-Life The mean terminal half-lives of total tetrahydrofolate and (6S)-5-methyl-5,6,7,8-tetrahydrofolate are 5.1 hours and 6.8 hours, respectively.The terminal half-life of total reduced folate is 6.2 hours. |
|---|---|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Drug Use During Lactation Leucovorin calcium (folate; 5-formyltetrahydrofolate) and its levorotatory isomer, levofolinate calcium, are folic acid derivatives and normal components of breast milk. Because levofolinate calcium and levofolinate calcium are often used in combination with potentially toxic drugs such as fluorouracil or methotrexate, relevant drug records in the LactMed database should be consulted. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. Protein Binding Does not bind to human serum albumin. |
| References |
Mofidifar S, Sohraby F, Bagheri M, Aryapour H. Repurposing existing drugs for new AMPK activators as a strategy to extend lifespan: a computer-aided drug discovery study. Biogerontology. 2018 Apr;19(2):133-143. doi: 10.1007/s10522-018-9744-x.
|
| Additional Infomation |
Pharmacodynamics
Levofolinic acid (LFO) can cross the cell membrane via both active and passive transport. In vivo, LFO is converted to 5-methyltetrahydrofolate (5-methyl-THF), the main circulating form of active reduced folate. LFO and 5-methyl-THF undergo polyglutamate modification within cells via folate polyglutamate synthase. Folate polyglutamate is active and participates in biochemical pathways requiring reduced folate. |
| Molecular Formula |
C20H23N7O7
|
|---|---|
| Molecular Weight |
473.439323663712
|
| Exact Mass |
473.166
|
| CAS # |
68538-85-2
|
| Related CAS # |
80433-71-2 (Ca);163254-40-8 (sodium);68538-85-2;
|
| PubChem CID |
135398559
|
| Appearance |
Crystals from water with 3 mol of water of crystallization.
|
| Melting Point |
245 °C (decomp)
|
| LogP |
1.152
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
34
|
| Complexity |
911
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
Nc1nc2NCC(CNc3ccc(cc3)C(=O)NC(CCC(O)=O)C(O)=O)N(C=O)c2c(=O)[nH]1
|
| InChi Key |
VVIAGPKUTFNRDU-STQMWFEESA-N
|
| InChi Code |
InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12-,13-/m0/s1
|
| Chemical Name |
(4-((((S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzoyl)-L-glutamic acid
|
| Synonyms |
LFP 754 LFP-754 LFP754 levo-Folinic Levofolene Levofolinic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1122 mL | 10.5610 mL | 21.1220 mL | |
| 5 mM | 0.4224 mL | 2.1122 mL | 4.2244 mL | |
| 10 mM | 0.2112 mL | 1.0561 mL | 2.1122 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer
CTID: NCT04745988
Phase: Phase 2 Status: Active, not recruiting
Date: 2024-11-15
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA